Bayer HealthCare Enhances Data Collection of EZ-Log Patient Electronic Diary

Share Article

New laser scanning technology makes tracking hemophilia treatment easier.

The new laser scanning technology now available with EZ-Log is part of Bayer HealthCare's commitment to provide regular product updates and enhancements that improve treatment tools

Bayer HealthCare today announced the addition of new laser scanning technology to its electronic patient diary system for hemophilia A patients. Now equipped with laser scanners, the enhanced Kogenate® FS, Antihemophilic Factor (Recombinant), EZ-Log Electronic Patient Diary provides more consistent record-keeping of treatment for both patients and healthcare professionals.

Through a handheld computer, EZ-Log allows patients to enter their treatment data in real-time by scanning barcodes of treatment packaging. Treatment data entered into the EZ-Log can be directly communicated to clinics and healthcare professionals online, greatly improving record-keeping compliance and communication between physicians and patients. EZ-Log also assists in ensuring infusions occur on time and allows patients to better manage their condition.

"EZ-Log is a great resource for people living with hemophilia," said Patrick Haggerty, a college senior with hemophilia A. "Keeping a record of when I infuse allows me to see when I'm incurring more bleeds and also holds me accountable for regular infusions."

The advantage of new laser scanners, which improve upon the previous optical scanning technology, is an increased ability to read and record the barcode information regardless of environmental factors, such as lighting conditions or scanning distances. The product enhancement answers a community need for better technology in data collection devices.

"Patient diaries are critical to managing hemophilia treatment," said Beverly Stevens, RN, BSN, Nurse Coordinator at the Okalahoma Center for Bleeding and Clotting Disorders. "The improved functionality of the laser scanner for Bayer's EZ-Log diary will not only benefit patients but also will help healthcare professionals track treatment regimens more accurately and make better recommendations for their patients."

Beginning in mid-December, all Kogenate® FS EZ-Log devices will be equipped with the new laser scanners. Patients can request an EZ-Log diary online at http://www.kogenatefs.com. Those currently using the electronic diary can upgrade their EZ-Log technology by requesting an installation kit available through their local hemophilia treatment center. All EZ-Log devices and equipment upgrades are free to Kogenate FS patients.

"The new laser scanning technology now available with EZ-Log is part of Bayer HealthCare's commitment to provide regular product updates and enhancements that improve treatment tools," said Terry Tenbrunsel, Vice President, Sales and Marketing, Bayer HealthCare. "At Bayer, we want to empower people living with hemophilia by providing them with the newest technology and most effective tools to manage their treatment."

Contact:
Kimberly Wix
Bayer HealthCare
Tel: (973) 305-5258
E-mail: kimberly.wix(at)bayer.com

About Kogenate® FS
Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. Please see the full prescribing information for important risk and use information at http://www.kogenatefs.com.

About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately one in 5,000 males born in the United States has hemophilia.

About Bayer HealthCare LLC
Bayer HealthCare LLC is an affiliate of Bayer HealthCare AG, one of the world's leading, innovative companies in the healthcare and medical products industry based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=180&contentid=45&rptname=bleeding

BAYER, the Bayer Cross and Kogenate are registered trademarks of Bayer.

©Bayer HealthCare LLC    091297Y

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kimberly Wix
Visit website